New asthma inhaler propellant tested for safety in completed study
NCT ID NCT05850494
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a new propellant (HFO) in asthma inhalers causes airway narrowing (bronchospasm) compared to the standard propellant (HFA). It involved 52 adults with well-controlled or partially controlled asthma. Researchers measured lung function right after use and checked for any breathing problems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
North Dartmouth, Massachusetts, 02747, United States
-
Research Site
St Louis, Missouri, 63141, United States
-
Research Site
Raleigh, North Carolina, 27607, United States
-
Research Site
El Paso, Texas, 79903, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tracking severe asthma over time unlock better treatments?
- Can pressurized breathing boost mucus clearance in lung disease?
- Can a simple breathing test unlock the secrets of chronic cough?
- Can a Breath-Activated inhaler match the standard for asthma control?
- Can a School-Home program tame childhood asthma?
- Could everyday supplements shield your lungs?